Senseonics And Mercy Announces That The First Commercial Patient Received The Next-Generation Eversense 365 CGM System
Portfolio Pulse from Benzinga Newsdesk
Senseonics Holdings, Inc. and Mercy have announced the first commercial use of the Eversense 365 CGM system, a long-term glucose monitoring device approved for use in the US. This marks a significant milestone in their collaboration, with a commercial launch by Ascensia Diabetes Care.
October 10, 2024 | 8:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Senseonics Holdings, Inc. has launched the Eversense 365 CGM system commercially, marking a significant milestone in diabetes care with its one-year monitoring capability.
The commercial launch of the Eversense 365 CGM system is a significant development for Senseonics, as it is the first CGM to offer a full year of monitoring. This could lead to increased adoption and sales, positively impacting the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100